Since IL-6 mediated the CaP-induced skin pruritus and p-ERK 1/2 activation in DRG (Figure 3), the use of BA-NH-NH-BA, a butyric acid analog, for suppression of CaP-induced pruritic inflammation may provide a new modality for the treatment of the pruritic condition in CKD. Here, IL6 is linked to chronic kidney disease.